27 Largest Biotech Companies in the US

Published on April 29, 2023 at 9:53 pm by Amnah Zaidi in Lists, News

In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion.

Latest Developments in the Biotech Industry

The biotechnology industry is making significant developments in food and agriculture to help minimize health risks and combat environmental threats. For example, a French biotech company called Enterome has collaborated with Nestlé to produce an immunity drug for the treatment of food allergies. Similarly, companies like UPSIDE Foods and BioBetter Limited are producing cultivated meat, which is sustainable and climate-friendly, and has gotten approved for safety by the U.S. Food and Drug Administration (FDA).

Experts in biotechnology are also producing various profitable products that are encouraging growth in the pharmaceutical sector. Researchers at the Massachusetts Institute of Technology have developed a vaccine printer that can make hundreds of vaccine patches during a day. This biotechnological invention can help combat the spread of the Ebola virus in countries that are still vulnerable to the epidemic such as Uganda and the Democratic Republic of Congo. CureVac N.V. (NASDAQ:CVAC) had begun developing RNA printing technology in March 2022 to help the invention of this vaccine printer.

To further enhance the integration of artificial intelligence with biotechnology, researchers at Insilico Medicine are using ChatGPT to pace up the process of discovering potential drug targets for treatment. Similarly, scientists are using software such as Scilife, Veeva Vault, and Ace, which support innovation in biotechnology by improving content and quality management in laboratories.

Currently, the most common diseases in the US are cancer, obesity, and heart-related diseases. Various biotechnology companies are making huge investments to combat these diseases such as Guardant Health, Inc. (NASDAQ:GH), which developed liquid biopsy for cancer detection; and Verve Therapeutics, Inc. (NASDAQ:VERV), which is developing gene editing medicines for cardiovascular diseases.

In order to combat diabetes, Novo Nordisk A/S (NYSE:NVO) produced medicines called Ozempic and Wegovy, which quickly garnered mass popularity and celebrity endorsements. These are also prescribed by American doctors for weight loss and fighting cardiovascular issues. Digital health management companies such as WeightWatchers and Lark Health are also using biotechnology to help patients cope with chronic diseases by offering weight loss programs and health monitoring devices.

Outlook of the Biotech Industry

The United States is the global leader in biotechnology, with Massachusetts being the biggest biotech hub in the world. It is closely followed by China, with the UK and the rest of Europe trailing behind. In response to China’s heavy investment in the biotechnology sector, the Biden government announced its creation of the National Biotechnology and Biomanufacturing Initiative, to support its bio-economy already worth $1 trillion in 2022.

Between 2022 and 2023, the S&P Biotechnology index increased by 8.86%. However, since the Federal Reserve is expected to increase interest rates through 2023, the value of biotech stocks might decrease compared to previous years, where the industry was supplied with huge investments and cheap capital to encourage the development of Covid 19 treatment.

Between 2022 and 2030, the global market is forecasted to grow at a compound annual rate of 13.9%, ultimately reaching $3879 billion in 2030. The development of genomic techniques to combat chronic diseases, enhancing the portability of biotechnological instruments, and the integration of robotics and biotechnology are predicted to be some of the key drivers of this industrial growth during the coming years.

Tonhom1009/Shutterstock.com

Our Methodology

For our list of the largest biotech companies in the US, we’ve ranked them in ascending order based on their annual revenue for the latest year. We’ve also included foreign companies that either trade or operate in the US.

Here are the 27 largest biotech companies in the US:

27. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

2022 Revenue: $8.93 billion

This biotech company specializes in the development and production of small-molecule drugs to treat serious ailments. The revenue for Vertex Pharmaceuticals increased by 17.4% in the fourth quarter of 2022 compared to the previous year, and the company is expected to make further gains after receiving FDA’s approval to expand its cystic fibrosis medicine.

26. Biogen Inc. (NASDAQ:BIIB)

2022 Revenue: $10.17 billion

Biogen Inc. (NASDAQ:BIIB) is a Massachusetts-based company that develops and delivers treatment for complex neurological illnesses such as Alzheimer’s and multiple sclerosis. Biogen Inc. (NASDAQ:BIIB) was the first company to gain approval for its treatment of spinal muscular atrophy.

25. CSL Limited

2022 Revenue: $10.49 billion

CSL Limited focuses on biotechnological advancement for combating rare diseases such as hereditary angioedema, producing vaccines for influenza, and treating iron deficiency in serious health conditions such as heart failure.

24. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

2022 Revenue: $12.17 billion

Regeneron Pharmaceuticals is a New York-based company that produces life-saving drugs for the treatment of serious diseases. Its highest-selling product is Libtayo, a medicine for skin cancer, which drove sales of approximately $448 million in 2022.

23. Otsuka Holdings Co., Ltd.

2022 Revenue: $13.02 billion

Otsuka Holdings is a Japanese company that conducts business in the global drugs and biotechnology industry. Otsuka Holdings Co. produces pharmaceuticals, neutraceuticals, and consumer products. In 2022, the company made a profit of $1.1 billion.

22. Laboratory Corporation of America Holdings (NYSE:LH)

2022 Revenue: $14.87 billion

Laboratory Corporation of America Holdings (NYSE:LH) is a biotech and healthcare company that has a network of 36 laboratories in America, which are used for diagnostics and drug development. Laboratory Corporation of America Holdings (NYSE:LH) is further expanding its business by buying Enzo Biochem, Inc. (NYSE:ENZ)’s clinical lab business for $146 million while also launching an independent clinical development business called Fortrea.

21. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

2022 Revenue: $14.92 billion

Teva Pharmaceutical Industries Limited (NYSE:TEVA) produces generic drugs and consumer healthcare solutions. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has a portfolio of 3600 medicines and health products, which are supplied to more than 200 million people in 60 countries across the world.

20. Baxter International Inc. (NYSE:BAX)

2022 Revenue: $15.11 billion

Baxter International Inc. produces healthcare solutions for the treatment of nutritional and renal ailments among others. In the last quarter of 2022, its biggest stakeholder was Generation Investment Management, which held more than 10 million shares of the company, worth a total of $553 million.

19. Viatris Inc. (NASDAQ:VTRS)

2022 Revenue: $16.26 billion

Viatris Inc. (NASDAQ:VTRS) is a Pennsylvania-based company that produces medicines, generic drugs, and pharmaceutical ingredients. Merely two years after its incorporation, Viatris Inc. (NASDAQ:VTRS) bought Oyster Point Pharma and Famy Life Sciences for $750 million and now aims to become a globally leading company in ophthalmology.

18. BioNTech SE (NASDAQ:BNTX)

2022 Revenue: $18.43 billion

BioNTech SE is a German biotech and immunotherapy company that is traded publicly in the US. During the Covid-19 pandemic, the company collaborated with Pfizer Inc. (NYSE:PFE) to utilize its innovative genetic technology for the production of vaccines, which helped nearly 5 billion people in 181 countries in fighting coronavirus.

17. Novo Nordisk A/S (NYSE:NVO)

2022 Revenue: $25.05 billion

Novo Nordisk is a Danish biotech and pharmaceutical company that has established production plants in nine countries across the world, including the US. Its primary focus is on producing medicine to treat obesity, diabetes, and hemophilia among other illnesses. Its most popular medicines are Ozempic and Wegovy.

16. Amgen, Inc. (NASDAQ:AMGN)

2022 Revenue: $26.32 billion

Amgen is one of the world’s biggest independent biotech and biopharmaceutical firms, that produces medicine for serious illnesses such as cancer and anemia. Amgen’s earnings for Q1 2023 amounted to $6.11 billion, a 2% decline compared to first-quarter earnings in 2022.

15. Gilead Sciences, Inc. (NASDAQ:GILD)

2022 Revenue: $27.28 billion

Gilead Sciences, Inc. (NASDAQ:GILD) produces medicine and therapy for the treatment of cancers, viral diseases, and inflammation. Gilead Sciences, Inc. (NASDAQ:GILD) helped roughly 12 million people across the world in recovering from the coronavirus disease.

14. Eli Lilly and Company (NYSE:LLY)

2022 Revenue: $28.54 billion

Eli Lilly and Company is famous for being the first biotech company to mass-produce Penicillin, which is the first antibiotic, and insulin. It is also the largest producer of psychiatric medicine such as Prozac and Zyprexa. The greatest share of Eli Lilly’s revenue is driven by the sale of Trulicity and Humalog, which treat diabetes.

13. Takeda Pharmaceutical Company Limited (NYSE:TAK)

2022 Revenue: $29.59 billion

Takeda Pharmaceutical is the largest Asian company in the biopharma sector. In March 2023, Takeda Pharmaceutical received an investment of $960,000 from the Global Health Innovative Technology (GHIT) Fund for the development of antimalarial medicine.

12. GSK plc (NYSE:GSK)

2022 Revenue: $38.94 billion

GSK is a global biotech and pharmaceutical company that produces vaccines, general medicine for primary care, and specialty medicine and therapy for cancer, HIV, and respiratory diseases. It is expanding its biotech operation in Canada by acquiring Bellus Health for $2 billion.

11. AstraZeneca PLC (NASDAQ:AZN)

2022 Revenue: $44.35 billion

AstraZeneca is a biotech company that produces medicine, vaccines, and immune therapy, specifically for type 2 diabetes, respiratory problems, and cancers. The company earned a profit of $1.8 billion in Q1 of 2023.

10. Thermo Fisher Scientific Inc. (NYSE:TMO)

2022 Revenue: $44.91 billion

Thermo Fisher Scientific is a biotechnology and healthcare distributor company that produces scientific instruments, software, and chemicals. In Q4 of 2022, its biggest stakeholder was Farallon Capital, which owned 1 million company shares, amounting to $639 million in total.

9. Bristol-Myers Squibb Company (NYSE:BMY)

2022 Revenue: $46.15 billion

Bristol-Myers Squibb ranks among the most prominent global companies in the biotechnology and pharmaceutical industries. The company has made a collaboration of $1 billion with Tubulis, a German biotechnology company, to develop and produce potent therapies for solid tumors and cancers.

8. Sanofi (NASDAQ:SNY)

2022 Revenue: $47.62 billion

Sanofi is a pharmaceutical and biotech company that produces vaccines and affordable medicine to provide quality healthcare in developing countries. The French company has acquired Provention Bio, Inc. (NASDAQ:PRVB), thus adding TZIELD–an innovative therapy for type 1 diabetes–to its portfolio.

7. Novartis AG (NYSE:NVS)

2022 Revenue: $51.82 billion

Novartis AG (NYSE:NVS) is one of the leading research and development companies that produces transformative treatments for serious medical issues. Novartis AG (NYSE:NVS) witnessed an increase in profit during the first quarter of 2023, which was mainly supported by sales of cardiovascular and cancer medicines.

6. Bayer AG

2022 Revenue: $53.67 billion

Bayer is a German pharmaceutical and biotech company that also produces consumer healthcare products along with chemicals and seeds for agriculture. According to the CEO, the company’s sales increased by 9% in 2022, even though it was a difficult year for businesses amid the energy crisis and inflation.

Click to continue reading and see the 5 Largest Biotech Companies in the US.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

27 Largest Biotech Companies in the US

Published on April 29, 2023 at 9:53 pm by Amnah Zaidi in Lists, News

Latest Developments in the Biotech Industry

Outlook of the Biotech Industry

Our Methodology

27. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

26. Biogen Inc. (NASDAQ:BIIB)

25. CSL Limited

24. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

23. Otsuka Holdings Co., Ltd.

22. Laboratory Corporation of America Holdings (NYSE:LH)

21. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

20. Baxter International Inc. (NYSE:BAX)

19. Viatris Inc. (NASDAQ:VTRS)

18. BioNTech SE (NASDAQ:BNTX)

17. Novo Nordisk A/S (NYSE:NVO)

16. Amgen, Inc. (NASDAQ:AMGN)

15. Gilead Sciences, Inc. (NASDAQ:GILD)

14. Eli Lilly and Company (NYSE:LLY)

13. Takeda Pharmaceutical Company Limited (NYSE:TAK)

12. GSK plc (NYSE:GSK)

11. AstraZeneca PLC (NASDAQ:AZN)

10. Thermo Fisher Scientific Inc. (NYSE:TMO)

9. Bristol-Myers Squibb Company (NYSE:BMY)

8. Sanofi (NASDAQ:SNY)

7. Novartis AG (NYSE:NVS)

6. Bayer AG

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

27 Largest Biotech Companies in the US

Published on April 29, 2023 at 9:53 pm by Amnah Zaidi in Lists, News

Share

Latest Developments in the Biotech Industry

Outlook of the Biotech Industry

Our Methodology

27. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

26. Biogen Inc. (NASDAQ:BIIB)

25. CSL Limited

24. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

23. Otsuka Holdings Co., Ltd.

22. Laboratory Corporation of America Holdings (NYSE:LH)

21. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

20. Baxter International Inc. (NYSE:BAX)

19. Viatris Inc. (NASDAQ:VTRS)

18. BioNTech SE (NASDAQ:BNTX)

17. Novo Nordisk A/S (NYSE:NVO)

16. Amgen, Inc. (NASDAQ:AMGN)

15. Gilead Sciences, Inc. (NASDAQ:GILD)

14. Eli Lilly and Company (NYSE:LLY)

13. Takeda Pharmaceutical Company Limited (NYSE:TAK)

12. GSK plc (NYSE:GSK)

11. AstraZeneca PLC (NASDAQ:AZN)

10. Thermo Fisher Scientific Inc. (NYSE:TMO)

9. Bristol-Myers Squibb Company (NYSE:BMY)

8. Sanofi (NASDAQ:SNY)

7. Novartis AG (NYSE:NVS)

6. Bayer AG

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff